Eyes absent homologue 2 predicts a favorable prognosis in colorectal cancer
Received 30 January 2018
Accepted for publication 10 May 2018
Published 8 August 2018 Volume 2018:11 Pages 4661—4671
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Jie Zheng,1,2,* Fuao Cao,3,* Xiaopei Huang,4,* Kuvaneshan Ramen,2 Xiaowen Xu,3 Yan Zhu,5 Wenjun Chang,4 Yunfeng Shan,2 Aizhen Guo1
1Department of General Medicine, Yangpu Hosptial, Tongji University School of Medicine, Shanghai 200090, People’s Republic of China; 2Department of General Surgery, First Affiliated Hospital, Wenzhou Medical University, Zhejiang 325015, People’s Republic of China; 3Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 4Department of Environmental Hygiene, Second Military Medical University, Shanghai 200433, People’s Republic of China; 5Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China
*These authors contributed equally to this work
Purpose: Eyes absent homologue 2 (EYA2), which functions as a transcription activator and phosphatase, plays an important role in several types of cancer. However, the impact of EYA2 in colorectal cancer (CRC) remains elusive.
Patients and methods: We evaluated the significance of EYA2 expression in the development and progression of CRC in a large cohort, including 922 CRC cases. EYA2 protein expression was determined via immunohistochemistry in colorectal tissues. The correlation between EYA2 expression and CRC occurrence was investigated in tumor tissue and the adjacent normal tissues. Factors contributing to CRC prognosis were evaluated using Kaplan–Meier and Cox model analyses.
Results: EYA2 expression was progressively lower in the adjacent normal tissue, adenomas, primary tumor and the metastatic CRC (all P<0.05). Furthermore, EYA2 expression had significant associations with disease stage, differentiation grade, and number of resected lymph nodes (all P<0.001). Compared with patients with EYA2-high tumors, those with EYA2-low tumors had shorter disease-free survival (hazard ratio [HR], 2.347; 95% CI, 1.665–3.308) and disease-specific survival (HR, 3.560; 95% CI, 2.055–6.167) in multivariate Cox analysis, after adjusting confounding factors such as tumor-node-metastasis stage and grade. In particular, patients with stage II or III EYA2-low CRC might be harmed by postoperative chemotherapy.
Conclusion: EYA2 expression was generally reduced in CRC. Higher EYA2 expression can predict a more favorable prognosis for CRC.
Keywords: colorectal cancer, EYA2, immunohistochemistry, prognosis, chemotherapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]